Trastuzumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17335 publications

Conversion therapy for hepatoid adenocarcinoma of the stomach: A case report

Conversion therapy for hepatoid adenocarcinoma of the stomach: A case report

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Published: April 14, 2026

Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context.

Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context.

Journal: Cancer investigation

Published: April 10, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies.

Methodological limitations in interpreting the efficacy of trastuzumab deruxtecan by CLDN18.2 status in single-arm studies.

Journal: ESMO gastrointestinal oncology

Published: April 09, 2026

Retraction: 3, 3'-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells.

Retraction: 3, 3'-diindolylmethane Enhances the Effectiveness of Herceptin against HER-2/Neu-Expressing Breast Cancer Cells.

Journal: PloS one

Published: April 08, 2026

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Journal: The New England journal of medicine

Published: April 03, 2026

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.

Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxic Effects.

Journal: JAMA oncology

Published: April 02, 2026

A Bispecific Antibody Engineering Strategy for Effective Dual-Target Degradation of Cell-Surface and Secreted Oncoproteins with Superior Antitumor Activity.

A Bispecific Antibody Engineering Strategy for Effective Dual-Target Degradation of Cell-Surface and Secreted Oncoproteins with Superior Antitumor Activity.

Journal: ACS chemical biology

Published: April 01, 2026

Visceral crisis in HER2-positive, AFP-producing gastric cancer.

Visceral crisis in HER2-positive, AFP-producing gastric cancer.

Journal: BMJ case reports

Published: March 31, 2026

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

CLO26-087: Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer: A Systematic Review and Meta-analysis.

CLO26-087: Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer: A Systematic Review and Meta-analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Effectiveness and safety of trastuzumab-anns compared to reference trastuzumab among patients with HER2-positive breast cancer: A non-inferiority study.

Effectiveness and safety of trastuzumab-anns compared to reference trastuzumab among patients with HER2-positive breast cancer: A non-inferiority study.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: March 27, 2026

Showing 1-12 of 17,335

Last Updated: 04/28/2026